Breast Cancer

Pumitamig/nab-paclitaxel produced responses in advanced TNBC in a phase 2 study, informing its further evaluation in the phase 3 ROSETTA Breast-01 trial.

With her collaborative ethos and patient-first focus, Lisa A. Carey, MD, ScM, FASCO, is driving innovation in breast cancer research and management.

Most premenopausal women with early breast cancer accepted GnRHa during chemotherapy to preserve ovarian function; cryopreservation uptake was lower.

A mobile health intervention was associated with improvements to general and cancer-specific quality of life in AYA breast cancer survivors.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

Heather McArthur, MD, MPH, FASCO, elaborates on clinical trial data for palazestrant monotherapy in breast cancers.

Experts convene during an OncLive Peer Exchange to discuss the evolving treatment paradigm in HR-positive, HER2-negative breast cancer.

Phase 1 data showed that LP-184 displayed an acceptable safety profile and was well-tolerated in heavily-pretreated patients with advanced solid tumors.

On October 6, 2025, a panel of medical oncologists specializing in advanced breast cancer participated in a virtual workshop to examine the optimization of testing strategies and treatment decisions for ESR1-mutated HR+/HER2- metastatic breast cancer.

Breast oncology experts discuss SABCS 2025 data from HER2CLIMB-05 and lidERA that may influence maintenance therapy and adjuvant endocrine care.

Eniluracil plus capecitabine showed signs of improved efficacy vs capecitabine alone while maintaining safety in advanced/metastatic breast cancer.

Omitting sentinel lymph node biopsy displayed noninferiority in select older patients with hormone receptor–positive breast cancer.

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

Imlunestrant alone or in combination with abemaciclib significantly improved PFS in ER-positive and HER2-negative breast cancer.

Neoadjuvant niraparib plus dostarlimab led to pathologic complete responses in BRCA- or PALB2-mutated triple-negative breast cancer.

Giredestrant plus everolimus improved PFS across subgroups in ER-positive/HER2-negative advanced breast cancer.

Sacituzumab govitecan combined with pembrolizumab showed a manageable safety profile with lower TEAE discontinuation rates in TNBC.

Menopausal hormone replacement therapy was not associated with an increased risk of breast cancer in women with BRCA mutations.

MRD as detected by a novel tumor-informed ctDNA assay helped identify patients with TNBC who were at higher risk for distant recurrence after surgery.

Gedatolisib regimens showed PFS benefits irrespective of prior treatment duration in HR-positive, HER2-negative PIK3CA wild-type advanced breast cancer.

An adjusted OS analysis showed no OS difference with the addition of adjuvant palbociclib in HR-positive/HER2-negative breast cancer.

Camizestrant plus continued CDK4/6 inhibition led to clinically meaningful improvements in PFS, PFS2, TTFST, TTSSS, and chemotherapy/ADC-free survival vs SOC.

Elacestrant plus abemaciclib or everolimus was safe and showed preliminary efficacy in ER-positive, HER2-negative advanced breast cancer.

Alpelisib plus fulvestrant improved PFS vs fulvestrant alone in PIK3CA-mutated, hormone receptor–positive/HER2-negative advanced breast cancer.